23andMe Seeks New Bid As Ex-CEO Enters The Arena

23andMe is considering reopening bidding for its assets after former CEO Anne Wojcicki, through her nonprofit TTAM Research Institute, submitted a $305 million offer, exceeding Regeneron Pharmaceuticals' previous $256 million bid; Regeneron is open to submitting a new bid but seeks a $10 million breakup fee if Wojcicki's offer is accepted. The bankruptcy proceedings follow 23andMe's failure to achieve profitability and a significant data breach in 2023, with Regeneron initially planning to acquire key assets, including its biobank and consumer genome services. In response to the news, 23andMe's holding company shares rose 20%, while Regeneron stock dipped slightly.

Analysis

Bankrupt genetics firm 23andMe (MEHCQ) is evaluating a new $305 million bid for its assets from TTAM Research Institute, a nonprofit established by former CEO Anne Wojcicki, which surpasses Regeneron Pharmaceuticals' (REGN) previous leading offer of $256 million. This development has prompted 23andMe to consider reopening the bidding process. Regeneron remains open to submitting a revised bid but is requesting a $10 million breakup fee should Wojcicki's offer ultimately be accepted. The news triggered a significant market reaction, with 23andMe's holding company shares increasing by 20% to $4.76, while Regeneron's stock experienced a slight decline of over 1% to $478.78. This bidding contest unfolds against the backdrop of 23andMe's financial struggles, including its failure to achieve profitability, substantial cash depletion, and a major 2023 data breach affecting approximately 7 million individuals, which resulted in a $30 million class-action lawsuit. The company filed for bankruptcy in March, at which time Wojcicki also resigned as CEO. Regeneron's initial plan involved acquiring 23andMe's core assets, notably its Personal Genome Service, Total Health and Research Services, and its extensive biobank of genetic samples, with an intent to maintain uninterrupted consumer genome services. The resolution of this intensified bidding situation is currently being managed through court proceedings.

Key Decisions for Investors

• Investors in 23andMe's holding company (MEHCQ) should note the stock's 20% surge reflects optimism for a higher recovery value from asset sales due to the increased bid, though the equity remains highly speculative given its bankruptcy status.
• For Regeneron (REGN) shareholders, this development introduces uncertainty regarding the acquisition's outcome and potential cost, with the requested $10 million breakup fee indicating a strategic move to mitigate risk if they are outbid.
• Market participants should monitor the court proceedings closely, as the competitive bidding for 23andMe's assets, particularly its biobank, underscores their perceived strategic value despite the company's operational failures and data security issues, and the final terms will dictate the implications for all parties involved.